相关实验视频

Updated: Jun 22, 2025

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

在c-Myc下游的聚胺和EIF5A低化赋予了BRAF突变黑色素瘤的向治疗耐药性

Byung-Sun Park^1,2, Heeju Jeon^1,2, Yeonseo Kim³

¹Medicinal Materials Research Center, Korea Institute of Science and Technology, 5 Hwarangro-14-Gil, SeongbukGu, Seoul, 02792, Republic of Korea.

Molecular cancer

|July 4, 2024

概括

向聚胺生物合成,特别是AMD1,可以克服黑色素瘤中的BRAF抑制剂耐药性. 这种方法涉及EIF5A低和线粒体呼吸,提供了一种改善患者治疗结果的策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物化学生物化学

背景情况:

BRAF抑制剂是标准黑色素瘤治疗方法,但耐药性限制了疗效.
黑色素瘤表现出多样化的抵抗机制,需要新的治疗点.
识别可用药的点来逆转耐药性对于有效的黑色素瘤治疗至关重要.

研究的目的:

确定能够克服黑色素瘤中BRAF抑制剂耐药性的新型可用药物标.
阐明BRAF抑制剂耐药性的基础分子机制.
在临床前黑色素瘤模型中验证潜在的治疗点.

主要方法:

在CRISPR-Cas9选中,AMD1被确定为耐维村法尼布黑色素瘤的标.
在体外和体外测试评估了协同作用的细胞死亡和抵抗逆转.
代谢,蛋白质和分子分析分析了聚胺生物合成,EIF5A低化和线粒体功能.
生物信息学与黑色素瘤患者预后相关的聚胺生物合成.

主要成果:

抑制AMD1,这是聚胺生物合成中的关键酶,逆转了维穆拉费尼布耐药性.
上调的聚胺生物合成增强了EIF5A的低化,线粒体蛋白转化和抗性黑色素瘤中的氧化酸化.
持续的c-Myc水平推动了高聚胺生物合成,其抑制也逆转了耐药性.
聚胺生物合成特征与黑色素瘤患者的预后不佳和较短的无进展生存时间相关.

结论:

聚胺-EIF5A低化-线粒体呼吸通路是黑色素瘤中BRAF抑制剂耐药性的关键机制.
准聚胺生物合成或c-Myc是一种可行的策略,可以提高BRAF抑制剂的疗效.
这些发现提供了新的治疗点,以改善对抗BRAF抑制剂的黑色素瘤患者的治疗结果.

关键词:

这就是BRAF.药物耐药性药物耐药性药物耐药性假设是指假设.黑色素瘤是一种黑色素瘤.线粒体中的线粒体.聚胺是一种聚胺.在Vemurafenib中使用.c-Myccc 的意思是我的

更多相关视频

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model

Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model

Published on: November 13, 2012

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Induced Pluripotent Stem Cells

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...